Avanafil

Phosphodiesterase 5 Inhibitor — GENITO URINARY SYSTEM AND SEX HORMONES

Key facts

Avanafil is an ofp drug in the Phosphodiesterase 5 Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2012. Its mechanism of action is classified as Phosphodiesterase 5 Inhibitors. DrugCentral lists 3 molecular targets, including PDE5A, PDE5A and PDE6C. Recorded indications include Impotence.

• Approval status: ofp (first approved 2012 by the FDA).
• Drug class: Phosphodiesterase 5 Inhibitor.
• Mechanism of action: Phosphodiesterase 5 Inhibitors.
• Molecular targets: PDE5A, PDE5A and PDE6C (3 listed in DrugCentral).
• Indications: Impotence.
• ATC code: G04BE10 (Drugs used in erectile dysfunction).
• Molecular formula: C23H26ClN7O3; molecular weight 483.96 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Impotence

Mechanism & targets

• Mechanism of action (MoA): Phosphodiesterase 5 Inhibitors
• Established pharmacologic class: Phosphodiesterase 5 Inhibitor

Molecular targets (3)

Target	Gene	Action	Activity
cGMP-specific 3',5'-cyclic phosphodiesterase	PDE5A	inhibitor	IC50 8.28
cGMP-specific 3',5'-cyclic phosphodiesterase	PDE5A	unknown	IC50 8.28
Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'	PDE6C	unknown	IC50 6.20

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2013-06-21	EMA	—	—
2012-04-27	FDA	—	VIVUS

ATC classification

ATC code	Therapeutic hierarchy
G04BE10	GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › UROLOGICALS › Drugs used in erectile dysfunction

Chemical structure

• Molecular formula: C₂₃H₂₆ClN₇O₃
• Molecular weight: 483.96 g/mol
• CAS number: —
• InChIKey: WEAJZXNPAWBCOA-INIZCTEOSA-N
• PubChem CID: 9869929

COC1=C(Cl)C=C(CNC2=NC(=NC=C2C(=O)NCC2=NC=CC=N2)N2CCC[C@H]2CO)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Avanafil used for?

DrugCentral lists the following indications for Avanafil: Impotence.

How does Avanafil work?

Avanafil is classified as Phosphodiesterase 5 Inhibitors; its molecular targets in DrugCentral include PDE5A (inhibitor), PDE5A and PDE6C.

When was Avanafil first approved?

Avanafil was first approved by the FDA in 2012.

What drug class does Avanafil belong to?

Avanafil is in the Phosphodiesterase 5 Inhibitor class.

What is the chemical formula of Avanafil?

Avanafil has the molecular formula C23H26ClN7O3 and a molecular weight of 483.96 g/mol.

Sources

• DrugCentral drug card 4305 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1963681 — compound record and bioactivity
• PubChem CID 9869929 — chemical identifiers
• DrugBank DB06237 — drug record
• FDA UNII DR5S136IVO — substance identity
• DailyMed: FDA labels for Avanafil — current prescribing information (label search)
• UniProt O76074 (PDE5A) — target protein
• UniProt P51160 (PDE6C) — target protein

How this page is built: methodology · editorial policy & corrections.